This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Agenus' Brain Cancer Vaccine Results To Be Presented At Plenary Session Of The 81st American Association Of Neurological Surgeons (AANS) Annual Scientific Meeting

LEXINGTON, Mass., April 10, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today that Orin Bloch, MD, Clinical Instructor, Department of Neurological Surgery, University of California San Francisco (UCSF), will present an abstract that reports on outcomes with HSPPC-96 vaccination in patients with newly diagnosed glioma at the 81 st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in New Orleans, Louisiana, April 27-May 1, 2013. Dr. Bloch's presentation will be given during Plenary Session III of the AANS meeting on May 1, 2013 at 10:19 am ET.

Dr. Bloch is a lead medical scientist working on the study at UCSF. Dr. Parsa, MD, Ph.D., who is currently at UCSF and will soon join Northwestern University as the newly appointed Chair of the Department of Neurological Surgery, is the lead clinical investigator for Prophage Series G-100 and G-200 in newly diagnosed and recurrent glioblastoma, respectively.

HSP Platform: The Prophage Series Cancer Vaccines

The Prophage Series of vaccines are patient-specific therapeutic cancer vaccine candidates. They contain heat shock protein gp96 and associated peptides that are purified from patient tumor tissue. Prophage Series vaccines are designed to target only cancerous cells, not healthy normal cells, and limit the toxicities associated with traditional broad-acting cancer treatments.

Prophage Series G-100 and G-200 are being studied in two different settings of glioma: newly diagnosed and recurrent disease. Glioma is the deadliest form of brain cancer with an average survival of six to 14 months.

Promising results from an earlier Phase 2 trial in patients with recurrent glioma treated with Prophage Series G-200 were presented at the 2012 AANS Annual Meeting. In the 2012 AANS presentation, over 40 patients were treated and the population evaluated for efficacy had a median Karnofsky performance status (KPS) of 80 and median age of 53. Patients treated with G-200 lived significantly longer than 86 consecutive patients not enrolled in the G-200 clinical trial, but treated with alternative therapies during the study period.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs